AstraZeneca, Dako Team on Companion Dx | GenomeWeb

NEW YORK (GenomeWeb News) – AstraZeneca and Dako Denmark announced today that they will collaborate on developing companion diagnostics for multiple AstraZeneca oncology drug programs.

The firms said that the AstraZeneca drug candidates will be biologics and small molecule drugs that are in various stages of development. They did not name specific cancer targets, nor did they provide any financial details of the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.